Astal Laboratories Reports Q4 FY26 Results

Consolidated Revenue: ₹134.05 crore
Consolidated Net Profit: ₹7.68 crore

Reader Takeaway: Subsidiary's strong performance boosts consolidated results; focus on bulk drugs business continues.

What just happened

Astal Laboratories Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported consolidated revenue of ₹134.05 crore and a consolidated net profit of ₹7.68 crore. Standalone figures showed revenue of ₹40.92 crore and a net profit of ₹1.09 crore.

The auditor provided an unmodified opinion on the financial statements.

Why this matters

The consolidated results offer a broader view of the company's financial performance, including the impact of its subsidiary, Sriven Pharmachem India Private Limited. The subsidiary's performance is a key driver of the group's overall revenue and profitability.

The backstory

Astal Laboratories operates primarily in the manufacturing and trading of Bulk Drugs (Active Pharmaceutical Ingredients). The consolidation of Sriven Pharmachem India Private Limited, acquired recently, has now significantly shaped the group's financial figures.

What changes now

Investors will now look at the combined entity's performance. The subsidiary's contribution is substantial, with ₹94.18 crore in revenue and ₹6.59 crore in net profit for the period it was part of the group (January 14, 2026, to March 31, 2026). The consolidated assets have increased to ₹518.19 crore from standalone assets of ₹399.57 crore.

Risks to watch

Investors should monitor the growth and performance of the single business segment, Bulk Drugs, under the new consolidated structure. The company's corporate identity and business focus have recently shifted, and sustained growth in this segment is key.

Peer comparison

(Information not available in the filing)

Context metrics (time-bound)

Q4 FY2026 Consolidated Performance:

• Revenue from operations: ₹134.05 crore
• Net Profit: ₹7.68 crore
• Basic EPS: ₹2.039

Q4 FY2026 Standalone Performance:

• Revenue from operations: ₹40.92 crore
• Net Profit: ₹1.09 crore
• Basic EPS: ₹0.288

Subsidiary (Sriven Pharmachem India Private Limited) Contribution (Jan 14, 2026 - Mar 31, 2026):

• Total Assets: ₹193.14 crore
• Total Revenue: ₹94.18 crore
• Net Profit After Tax: ₹6.59 crore

What to track next

Investors should keep an eye on the company's future quarterly results to gauge the sustained contribution of Sriven Pharmachem and the overall growth trajectory of the bulk drugs business.